Roche pulled the plug on olesoxime, the spinal
muscular atrophy drug it acquired for €120 million upfront three years ago.
(Roche)
Roche has stopped development of the spinal muscular
atrophy (SMA) drug it acquired for €120 million ($140 million) upfront three
years ago. The Swiss pharma is walking away from olesoxime after running into
“many difficulties in developing” the oral mitochondria-boosting drug.
In a statement to the SMA community shared online by TreatSMA,
Roche walks through the issues that have stopped olesoxime from powering forward.
The company has struggled with everything from formulation to dose selection
and the demands of regulatory agencies for a phase 3 trial.
Roche spent several years working through these
issues, only for data from a midphase trial to raise doubts about whether
olesoxime is worth the hassle. The 18-month readout shared in April suggested
the efficacy of olesoxime wanes over time. While the drug initially helped
participants, by 18 months their motor function was deteriorating.
Biopharma is a fast-growing world where big ideas come
along daily. Our subscribers rely on FierceBiotech as their must-read source
for the latest news, analysis and data in the world of biotech and pharma
R&D. Sign up today to get biotech news and updates delivered to your inbox
and read on the go.
The disappointing data look to have deterred Roche
from persisting with olesoxime. In explaining the decision, Roche pointed to
recent changes in the treatment options available to patients with SMA. When
Roche acquired olesoxime, there were no approved drugs for SMA. Now, patients
have access to Biogen and Ionis’ Spinraza and can look forward to experimental
treatments including AveXis’ gene therapy.
That has changed both the commercial and clinical
development environments for SMA drugs.
“The emergence of effective treatment has raised the
hurdle for how effective a new treatment needs to be, and this has an impact on
how we design and run our clinical studies,” Sangeeta Jethwa, M.D., Roche's
head of patient partnerships and rare diseases, wrote in a letter to the SMA
community.
Faced with that level of competition, Roche has
decided it makes little sense to struggle forward with a drug that may only
offer marginal efficacy. Instead, it is switching attention from SMA to
its oral SMN2 splicing modifier RG7916.
The decision means Roche’s gamble on olesoxime has
failed to pay off. When Roche paid €120 million and committed €350 million in
milestones to buy French biotech Trophos, olesoxime had already failed to move
the needle in a phase 3 amyotrophic lateral sclerosis trial. That cost Trophos
its chance of being bought by Alexion, but its pivot to SMA paid off four years
later when Roche swooped in.
by Nick Paul Taylor | FierceBiotech
0 comentários:
Postar um comentário